Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
22 sept. 2021 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford...
Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
22 sept. 2021 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
15 juil. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
18 mai 2021 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
18 mai 2021 02h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica plc Preliminary results for the year ended 31 December 2020
15 avr. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading cell and...
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors
06 avr. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors Oxford, UK – 6 April, 2021: Oxford...
Oxford Biomedica plc: Board Changes
03 févr. 2021 07h00 HE
|
Oxford BioMedica plc
Board Changes Oxford, UK – 3 February, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces two changes to the...
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK
30 déc. 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”...
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director
23 nov. 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and...